Zenas BioPharma (NASDAQ:ZBIO) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Zenas BioPharma (NASDAQ:ZBIO) posted its quarterly earnings results on Wednesday. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.09), FiscalAI reports. During the same quarter in the prior year, the business posted ($0.80) earnings per share.

Zenas BioPharma Price Performance

Shares of Zenas BioPharma stock traded up $0.77 during trading on Wednesday, hitting $19.93. 516,448 shares of the company were exchanged, compared to its average volume of 863,871. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -2.55 and a beta of -0.61. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma has a fifty-two week low of $8.53 and a fifty-two week high of $44.60. The firm has a 50 day moving average price of $21.59 and a 200 day moving average price of $26.88.

Insider Activity

In other news, Director Hongbo Lu bought 3,768 shares of the stock in a transaction on Tuesday, March 31st. The stock was purchased at an average cost of $18.63 per share, with a total value of $70,197.84. Following the purchase, the director owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. The trade was a 0.89% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Patricia L. Allen acquired 4,160 shares of the stock in a transaction dated Friday, February 13th. The shares were bought at an average cost of $26.36 per share, with a total value of $109,657.60. Following the completion of the purchase, the director directly owned 19,860 shares in the company, valued at approximately $523,509.60. This trade represents a 26.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 233,628 shares of company stock valued at $4,637,200 over the last quarter. Insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors have recently made changes to their positions in ZBIO. Federated Hermes Inc. grew its stake in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares during the period. NEA Management Company LLC boosted its stake in shares of Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Zenas BioPharma in the fourth quarter worth $7,013,000. Vanguard Group Inc. raised its stake in shares of Zenas BioPharma by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after purchasing an additional 170,546 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Zenas BioPharma in the 4th quarter valued at about $5,950,000.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ZBIO shares. Guggenheim raised their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, March 17th. Citigroup reduced their target price on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Zacks Research downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.